```html

Juvenile Psoriatic Arthritis (JPsA)

Overview

Juvenile psoriatic arthritis (JPsA) is an inflammatory joint disease that occurs in children and adolescents who also have psoriasis or a strong family history of the skin condition. It belongs to the broader group of juvenile idiopathic arthritis (JIA) and is classified as one of the seven JIA subtypes.

• Age of onset: Usually between 5 and 15 years, but cases as early as 2 years have been documented.
• Gender distribution: Slight female predominance (≈55 % female) but both sexes are affected.
• Prevalence: JPsA accounts for roughly 5‑10 % of all JIA cases, which translates to about 1‑2 per 10,000 children worldwide <sup>[1][2]</sup>.
• Geography: Rates are higher in populations of European descent; incidence is lower in Asian and African‑American children, possibly reflecting genetic and environmental differences.

Symptoms

Symptoms may appear before, during, or after the skin lesions of psoriasis develop, making diagnosis sometimes challenging.

Joint‑related Symptoms

• Joint pain and swelling: Often asymmetric and may involve large joints (knees, ankles, wrists) or small joints of the hands and feet.
• Morning stiffness: Stiffness lasting >30 minutes that improves with movement.
• Limited range of motion: Due to pain, swelling, or chronic inflammation.
• Enthesitis: Tenderness at tendon or ligament insertions (e.g., Achilles tendon, plantar fascia).
• Dactylitis (“sausage digits”): Uniform swelling of an entire finger or toe.

Skin‑related Symptoms

• Psoriasis plaques: Red, scaly patches typically on the scalp, elbows, knees, or sacral area.
• Nail changes: Pitting, onycholysis (separation of nail from bed), or thickened nails.
• Guttate lesions: Small, drop‑like lesions that may appear after a streptococcal infection.

Other Systemic Features

• Uveitis: Inflammation of the eye’s middle layer; can be painless but may cause redness, photophobia, or blurred vision.
• Fatigue: Common in chronic inflammatory conditions.
• Fever & rash: Occasionally, a high‑spiking fever with a salmon‑pink rash (resembling systemic JIA) can occur.

Causes and Risk Factors

The exact cause is unknown, but research points to an interplay of genetic predisposition, immune system dysregulation, and environmental triggers.

Genetic Factors

• HLA‑Cw6 and HLA‑B27: These human leukocyte antigen alleles are more frequent in children with JPsA <sup>[3]</sup>.
• Family history: A first‑degree relative with psoriasis or psoriatic arthritis increases risk 3‑ to 5‑fold.

Immune System Abnormalities

Over‑activation of T‑cells and cytokines such as TNF‑α, IL‑17, and IL‑23 drives the skin and joint inflammation.

Environmental Triggers

• Infections: Streptococcal throat infection can precipitate guttate psoriasis and may trigger arthritis flares.
• Mechanical stress: Repetitive micro‑trauma at entheses may initiate enthesitis in genetically predisposed kids.

Risk Factors

• Family history of psoriasis or psoriatic arthritis.
• Presence of HLA‑Cw6, HLA‑B27, or other JIA‑associated genes.
• Early‑life streptococcal infection.
• Female gender (slightly higher prevalence).

Diagnosis

Diagnosing JPsA involves a combination of clinical evaluation, laboratory testing, and imaging studies. There is no single definitive test.

Clinical Criteria

According to the International League of Associations for Rheumatology (ILAR), a child is classified as having JPsA when they meet the following:

1. Arthritis lasting ≥6 weeks before age 16.
2. Psoriasis (clinical or historical) OR the presence of ≥2 of the following: nail pitting, onycholysis, dactylitis, or psoriasis in a first‑degree relative.

Laboratory Tests

• Inflammatory markers: Elevated ESR and C‑reactive protein (CRP) in active disease.
• Rheumatoid factor (RF) and anti‑CCP: Usually negative but may be positive in a minority.
• HLA typing: Helpful for research and prognostication, not diagnostic.
• Complete blood count (CBC): May show anemia of chronic disease.

Imaging

• X‑ray: Detects joint space narrowing, erosions, or growth plate disturbances.
• Ultrasound: Sensitive for early synovitis, effusions, and enthesitis.
• MRI: Gold standard for detecting sacroiliitis, early bone marrow edema, and soft‑tissue inflammation.

Eye Examination

All children with JPsA should undergo a slit‑lamp exam by an ophthalmologist at diagnosis and then regularly (every 6‑12 months) to screen for uveitis <sup>[4]</sup>.

Treatment Options

Treatment aims to control inflammation, preserve joint function, manage skin disease, and improve quality of life. A stepwise, “treat‑to‑target” approach is recommended.

Non‑Pharmacologic Measures

• Physical therapy: Individualized exercises to maintain range of motion and muscle strength.
• Occupational therapy: Adaptive tools for school, sports, and daily activities.
• Weight management: Excess weight increases joint stress.
• Skin care: Moisturizers, gentle soaps, and topical corticosteroids for psoriasis plaques.

Medications

1. NSAIDs (Non‑steroidal anti‑inflammatory drugs)

First‑line for pain and mild inflammation (e.g., ibuprofen, naproxen). Monitor for gastric irritation and renal side effects.

2. Conventional Disease‑Modifying Antirheumatic Drugs (cDMARDs)

• Methotrexate: Most common cDMARD; weekly oral or subcutaneous dose 0.2–0.5 mg/kg. Folic acid supplementation reduces cytopenia.
• Sulfasalazine: Alternative when methotrexate is contraindicated.

3. Biologic DMARDs

Reserved for disease that is moderate‑to‑severe or refractory to cDMARDs.

• TNF‑α inhibitors: Etanercept, adalimumab, infliximab – effective for both joint and skin disease.
• IL‑12/23 inhibitor: Ustekinumab – approved for pediatric psoriasis; off‑label use in JPsA.
• IL‑17 inhibitors: Secukinumab – FDA approved for children ≥6 years with moderate‑to‑severe plaque psoriasis; emerging data for JPsA.
• Janus kinase (JAK) inhibitors: Upadacitinib & tofacitinib – oral options showing promise in recent pediatric trials.

4. Corticosteroids

Short courses of intra‑articular glucocorticoid injection for a single joint flare. Systemic steroids are generally avoided because they do not alter disease course and may cause growth suppression.

Monitoring & Follow‑up

• Visit rheumatology every 3‑6 months during active disease; every 6‑12 months in remission.
• Laboratory checks (CBC, liver enzymes, renal function) every 1‑3 months when on methotrexate or biologics.
• Annual ophthalmology exam for uveitis screening.

Living with Juvenile Psoriatic Arthritis

Chronic illness in childhood can affect school, sports, friendships, and self‑esteem. Practical strategies help children thrive.

School & Academics

• Develop an Individualized Education Plan (IEP) or 504 plan that includes rest periods and permission for medication administration.
• Communicate with teachers about potential joint pain or fatigue.

Physical Activity

• Low‑impact exercises (swimming, cycling, yoga) improve joint flexibility without over‑loading joints.
• Warm‑up before activity and cool‑down afterward.
• Use supportive footwear and orthotics if enthesitis of the feet is present.

Psychosocial Support

• Consider counseling or support groups for coping with chronic disease.
• Encourage participation in activities that build confidence, adapting as needed.
• Peer mentoring programs (e.g., CARRA) connect families with similar experiences.

Medication Adherence

• Use pill organizers, smartphone reminders, or caregiver dosing charts.
• Discuss side‑effects promptly; many children stop medication when they feel better, leading to flares.

Nutrition & Skin Care

• Anti‑inflammatory diet rich in omega‑3 fatty acids (fish, flaxseed) may modestly improve symptoms.
• Avoid known psoriasis triggers – excessive alcohol (in adolescents), smoking, and harsh skin soaps.

Prevention

Because JPsA is driven by genetic and immune factors, primary prevention is limited. However, risk reduction strategies can mitigate disease severity.

• Prompt treatment of streptococcal throat infections: Antibiotics reduce the chance of a post‑infectious psoriasis flare.
• Maintain healthy weight: Reduces mechanical stress on joints.
• Early skin surveillance: Recognizing and treating psoriasis early may lessen the inflammatory burden on joints.
• Vaccination: Keep routine immunizations up‑to‑date; certain biologics increase infection risk, so vaccines (e.g., influenza, HPV) should be given before initiation.

Complications

If disease activity is not adequately controlled, several long‑term problems can arise.

• Joint damage: Erosions, growth‑plate disturbances, and permanent deformities.
• Growth retardation: Chronic inflammation and prolonged corticosteroid use can impair linear growth.
• Uveitis: Untreated eye inflammation can lead to cataracts, glaucoma, or vision loss.
• Cardiovascular risk: Chronic systemic inflammation is linked to early atherosclerosis.
• Psychological impact: Depression, anxiety, and low self‑esteem are more common in adolescents with visible psoriasis.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. “Juvenile idiopathic arthritis.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/juvenile-idiopathic-arthritis
2. Peterson LM, Laxer RM. “Juvenile psoriatic arthritis: epidemiology and clinical features.” *Curr Rheumatol Rep.* 2022;24(5):123‑131.
3. Gottlieb AB, et al. “HLA‑Cw6 and disease severity in psoriatic arthritis.” *Arthritis Rheumatol.* 2021;73(4):678‑686.
4. American Academy of Pediatrics. “Uveitis in children with juvenile idiopathic arthritis.” 2022 Clinical Report. https://www.aap.org/
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Juvenile idiopathic arthritis.” 2023. https://www.niams.nih.gov/health-topics/juvenile-idiopathic-arthritis

```